CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Conflict of Interest

Identification and management of conflicts of interest preserve the objectivity and credibility of CADTH programs and processes, and are intended to ensure the highest ethical standards and maintenance of integrity of the work undertaken and/or sponsored by CADTH. CADTH has in place conflict of interest policies and guidelines for all employees, external experts, committee or panel members, and individuals contracted by CADTH. All experts, patient representatives, and CADTH staff members involved in the CADTH Scientific Advice Program are bound by the conflict of interest policies and guidelines.

Conflict of Interest and Scientific Advice

  • Current members of the CADTH Canadian Drug Expert Committee (CDEC) or CADTH pan-Canadian Oncology Drug Review Expert Review Committee (pERC) will not participate in the Scientific Advice Program; however, past members of CDEC or pERC may participate, if appropriate.
  • A current member of CDEC or pERC, who has participated in providing Scientific Advice for a drug prior to appointment on the committee, will not participate in discussions, deliberations, and recommendations for the same drug if it is later submitted to CADTH through the CADTH Common Drug Review (CDR) or the CADTH pan-Canadian Oncology Drug Review (pCODR).
  • Experts who have knowledge of the contents of the CADTH Record of Scientific Advice for a drug, or who have attended the Scientific Advice meeting for a drug, will not participate in the review for the same drug with the same indication when submitted to CADTH through CDR or pCODR. Exceptions may apply.

For links to CADTH conflict of interest guidelines and policies, please refer to Conflict of Interest on the main CADTH website.